English
This article is from Indian Journal of Human Genetics , volume 18 . Abstract CONTEXT:: Factor V Leiden mutation is the most common inherited predisposition for hypercoagulability and thereby a common genetic cause for initiation of oral anti-coagulation therapy. There is a dearth of knowledge of coumarin response profile in such thrombophilic population. AIMS:: The current pilot study aims to estimate coumarin sensitivity in an Indian cohort with an inherited thrombophilia risk factor (Factor V Leiden mutation carriers) based on the observed frequency of CYP2C9*2, *3 and VKORC1-1639G >A genotype combinations. SETTINGS AND DESIGN:: A retrospective study carried out in a tertiary health care center in India. MATERIALS AND METHODS:: Carriers of FVL mutation were genotyped for CYP2C9 (*2, F*3) and VKORC1 (-1639G >A) variants by PCR-RFLP technique. STATISTICAL ANALYSIS USED:: Chi-square test to analyze difference in expected and observed genotype frequency. RESULTS:: Sixty-one (n = 61) unrelated carriers of FVL mutation were observed in the 13 years study period. The allele frequency of CYP2C9*2, CYP2C9*3, and VKORC1-1639A in this cohort was 0.06, 0.11, and 0.16, respectively. Six (9.7%
Sign in with your free account to read, download EPUBs or listen.
Ebook · Pharmacogenetic typing for oral anti-coagulant response among factor V Leiden mutation carriers. · Nahar, Risha, Saxena, Renu, Deb, Roumi, Verma, Ishwar C. · Internet Archive